Immunotherapy failure in adrenocortical cancer: where next?

Immunotherapy failure in adrenocortical cancer: where next?

Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in adv...

Full description

Bibliographic Details
Main Authors: Deborah Cosentini, Salvatore Grisanti, Alberto Dalla Volta, Marta Laganà, Chiara Fiorentini, Paola Perotti, Sandra Sigala, Alfredo Berruti
Format: Article
Language:English
Published: Bioscientifica 2018-11-01
Series:Endocrine Connections
Online Access:https://ec.bioscientifica.com/view/journals/ec/7/12/EC-18-0398.xml
id doaj-ea4f1600029a43529728f1ef2ca7aa0d
record_format Article
spelling doaj-ea4f1600029a43529728f1ef2ca7aa0d2020-11-25T00:52:57ZengBioscientificaEndocrine Connections2049-36142049-36142018-11-01712E5E8https://doi.org/10.1530/EC-18-0398Immunotherapy failure in adrenocortical cancer: where next?Deborah Cosentini0Salvatore Grisanti1Alberto Dalla Volta2Marta Laganà3Chiara Fiorentini4Paola Perotti5Sandra Sigala6Alfredo Berruti7Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, ItalyMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, ItalyMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, ItalyMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, ItalySection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyInternal Medicine, Department of Clinical and Biological Sciences, San Luigi Hospital, University of Turin, Orbassano, ItalySection of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyMedical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, ASST Spedali Civili, Brescia, ItalyImmunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.https://ec.bioscientifica.com/view/journals/ec/7/12/EC-18-0398.xml
collection DOAJ
language English
format Article
sources DOAJ
author Deborah Cosentini
Salvatore Grisanti
Alberto Dalla Volta
Marta Laganà
Chiara Fiorentini
Paola Perotti
Sandra Sigala
Alfredo Berruti
spellingShingle Deborah Cosentini
Salvatore Grisanti
Alberto Dalla Volta
Marta Laganà
Chiara Fiorentini
Paola Perotti
Sandra Sigala
Alfredo Berruti
Immunotherapy failure in adrenocortical cancer: where next?
Endocrine Connections
author_facet Deborah Cosentini
Salvatore Grisanti
Alberto Dalla Volta
Marta Laganà
Chiara Fiorentini
Paola Perotti
Sandra Sigala
Alfredo Berruti
author_sort Deborah Cosentini
title Immunotherapy failure in adrenocortical cancer: where next?
title_short Immunotherapy failure in adrenocortical cancer: where next?
title_full Immunotherapy failure in adrenocortical cancer: where next?
title_fullStr Immunotherapy failure in adrenocortical cancer: where next?
title_full_unstemmed Immunotherapy failure in adrenocortical cancer: where next?
title_sort immunotherapy failure in adrenocortical cancer: where next?
publisher Bioscientifica
series Endocrine Connections
issn 2049-3614
2049-3614
publishDate 2018-11-01
description Immunotherapy is widely used in the treatment of different cancer types, including metastatic melanoma, non-small cell lung cancer, renal cell carcinoma and urothelial cancer. The results of the phase I JAVELIN study failed to demonstrate a substantial activity of the PDL-1 inhibitor Avelumab in advanced adrenocortical carcinoma (ACC). This editorial focus on the possible mechanisms of ACC immunoevasion and suggests strategies to overcome the intrinsic immunotherapy resistance of this disease.
url https://ec.bioscientifica.com/view/journals/ec/7/12/EC-18-0398.xml
work_keys_str_mv AT deborahcosentini immunotherapyfailureinadrenocorticalcancerwherenext
AT salvatoregrisanti immunotherapyfailureinadrenocorticalcancerwherenext
AT albertodallavolta immunotherapyfailureinadrenocorticalcancerwherenext
AT martalagana immunotherapyfailureinadrenocorticalcancerwherenext
AT chiarafiorentini immunotherapyfailureinadrenocorticalcancerwherenext
AT paolaperotti immunotherapyfailureinadrenocorticalcancerwherenext
AT sandrasigala immunotherapyfailureinadrenocorticalcancerwherenext
AT alfredoberruti immunotherapyfailureinadrenocorticalcancerwherenext
_version_ 1725239989026947072

Similar Items